In silico validation of a new classifier, PCSCGier , for predicting recurrence-free survival in prostate cancer patients: Evidence from multiple datasets

Meng Zhang; Zichen Bian; Jia Chen; Lei Chen; Jun Zhou; Qingsong Niu; Zongyao Hao; Jialin Meng; Chaozhao Liang

doi:10.1002/ctm2.1105

In silico validation of a new classifier, PCSCG_ier , for predicting recurrence-free survival in prostate cancer patients: Evidence from multiple datasets

Clin Transl Med. 2023 Jan;13(1):e1105. doi: 10.1002/ctm2.1105.

Authors

Meng Zhang^{1

2

3

4}, Zichen Bian^{1

2

3}, Jia Chen^{1

2

3}, Lei Chen^{1

2

3}, Jun Zhou^{1

2

3}, Qingsong Niu^{1

2

3}, Zongyao Hao^{1

2

3}, Jialin Meng^{1

2

3

4}, Chaozhao Liang^{1

2

3}

Affiliations

¹ Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
² Institute of Urology, Anhui Medical University, Hefei, China.
³ Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Hefei, China.
⁴ Institute of Urology of Shenzhen University, The Third Affiliated Hospital of Shenzhen University, Shenzhen Luohu Hospital Group, Shenzhen, China.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers, Tumor
Humans
Male
Prostatic Neoplasms* / diagnosis

Substances

Biomarkers, Tumor